Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers.

Scientific reports·2026
Same author

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Innovative therapeutic cancer vaccine PDC<sup>∗</sup>lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.

ESMO open·2025
Same author

Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis.

ESMO open·2025
Same author

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.

ESMO open·2025

Related Experiment Video

Updated: Jun 19, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Treatment sequences in EGFR mutant advanced NSCLC.

M Wespiser1, A Swalduz1, M Pérol1

  • 1Department of Medical Oncology, Centre Léon Bérard, 28 rue Laënnec, 69008 Lyon, France.

Lung Cancer (Amsterdam, Netherlands)
|July 24, 2024
PubMed
Summary

EGFR mutations drive non-small cell lung cancer (NSCLC). While EGFR tyrosine kinase inhibitors (TKIs) improve survival, resistance develops, necessitating novel therapeutic strategies for advanced NSCLC patients.

Keywords:
Advanced non-small cell lung cancerEGFR mutationSystematic ReviewTreatment sequence

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Experiment Videos

Last Updated: Jun 19, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Common Epidermal Growth Factor Receptor (EGFR) gene mutations, including exon 19 deletion and L858R in exon 21, are primary actionable genomic alterations in non-small cell lung cancer (NSCLC).
  • Third-generation EGFR tyrosine kinase inhibitors (TKIs) represent a new standard in first-line treatment for advanced NSCLC, significantly altering disease progression and survival rates.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for advanced NSCLC with common EGFR mutations.
  • To discuss methods for overcoming resistance mechanisms and managing residual disease.
  • To propose a management algorithm for clinicians, integrating clinical and biological parameters.

Main Methods:

  • Review of published and forthcoming advances in NSCLC treatment.
  • Analysis of therapeutic strategies targeting EGFR mutations and resistance pathways.
  • Development of a clinical decision-making algorithm.

Main Results:

  • EGFR TKIs have improved survival, but resistance and heterogeneity limit long-term outcomes.
  • Combination therapies show promise for progression-free survival but may increase side effects.
  • Diverse therapeutic sequences are emerging for advanced NSCLC with EGFR mutations.

Conclusions:

  • New treatment options offer potential for improved outcomes in advanced NSCLC with EGFR mutations.
  • Further understanding of the impact on survival and quality of life is needed.
  • A personalized management approach considering clinical and biological factors is crucial.